Since then, after continuing to Shenzhen and Anhui, Shanghai has also made efforts in mergers and acquisitions.Since the second half of 2024, there have been frequent large-scale acquisitions in the A-share market, and the biomedical industry has accelerated its integration. For example, China Bio-Pharmaceutical intends to acquire about 55% equity of Haooubo by means of "agreement+offer", Qianhong Pharmaceutical plans to invest 390 million yuan for bankruptcy and reorganization of Fiona Fang Pharmaceutical, Pharmacists help to acquire a piece of medicine, Xinnuowei plans to acquire 100 grams of Shiyao, and Sichuan Shuangma announced the cross-border acquisition of Jianyuan Medicine ...A 10 billion yuan M&A fund for biomedical industry will also be set up.
In addition to the integrated circuit design industry, Shanghai will also set up a M&A fund for the biomedical industry with a scale of 10 billion yuan.Bu Rixin said that only through mergers and acquisitions and accelerating industrial integration can the benign development of the industry be promoted, which is also one of the most effective measures.
"Because the industry is a typical' big money' industry, that is, high risk, long cycle and burning money, the nature of biomedicine also determines that it needs mergers and acquisitions in the current environment to become bigger and stronger."However, in the field of large chips such as GPU, it has not yet run out of listed companies. It can be seen that Moore Thread, Biwa Technology, Suiyuan Technology, etc. have started the listing counseling process one after another.Unlike Shenzhen and Anhui, which made good use of "green channel" policies such as debt financing, mergers and acquisitions, and vigorously developed equity-based M&A funds, this time Shanghai directly gave the scale of M&A funds.
Strategy guide 12-14
Strategy guide
12-14
Strategy guide 12-14
Strategy guide
12-14
Strategy guide 12-14